Archive for the 'Novel Treatments & Drugs' Category

Novel Treatments & Drugs news feed.

ONCOS-102 Passes Safety Evaluation in Phase I Clinical Trials, Phase II Clinical Trial Recommended

A new immunotherapy developed by Targovax has recently passed Phase I clinical trials and is set to begin Phase II evaluation of this new treatment that may help those suffering from mesothelioma. ONCOS-102 was used in separate Phase I clinical trials; one in combination with chemotherapy, and one with immunotherapy. Cisplatin and pemetrexed are two

more

Legitimate Data and Research is Required for Treatment Approval

For cancer patients who have little success with traditional chemotherapy and radiation treatments, immunotherapy treatments are becoming known alternatives – working with the body’s own immune system to become stronger and better able to fight cancer cells and other infections. A mesothelioma diagnosis is often grim, with survival rates at approximately one year at diagnosis.

more

Autophagy Inhibitors Potentially Make Chemotherapy More Effective in Mesothelioma Patients

Autophagy is a natural and regulated self-degradative process in cells that plays a critical role in balancing sources of energy and removing aggravated proteins, damaged organelles, and pathogens. During autophagy, cells break down and recycle their different parts in order to make new cells. In mesothelioma, autophagy is necessary for mesothelial cell growth. A recent

more

Bevacizumab – A Positive Treatment with Serious Side Effects

Bevacizumab (Avastin) is commonly viewed as chemotherapy treatment because when administered intravenously, it is particularly effective in controlling such illnesses such as lung cancer and colon cancer. However, it is a bit different than traditional chemotherapy treatments, which directly attack cancer cells. Bevacizumab fights cancer cells by cutting off oxygen and other nutrients the cells

more

The Effectiveness of Cisplatin and Pemetrexed in Pericardial Mesothelioma

Out of all the types of mesothelioma, pericardial mesothelioma is one of the rarest forms, accounting for only 0.002% of all known diagnosed mesothelioma cases. Mesothelioma is caused by asbestos exposure, and despite this knowledge and years of research, scientists and researchers still do not have a clear answer as to how the asbestos fibers

more

Opdivo, Yervoy, and Keytruda: Immunotherapy Options for Mesothelioma

Immunotherapy treatments are becoming known alternatives to chemotherapy in cancer patients who have had little success with traditional cancer treatments. With mesothelioma, often times first line treatments have little effect because the cancer is typically in the advanced stages by the time it is detected.  While there currently is no cure for mesothelioma, scientists and

more

Determining and Prolonging Survival Rates In Mesothelioma

The average survival rate for mesothelioma after diagnosis is less than one year; however, certain individuals will survive longer than others, but the reason as to why this is, is largely unknown.  The latest study to be published in Histopathology investigates what it is in the body that determines a higher survival rate in some,

more

Trimodality Therapy Increases Survival; Immunotherapy Treatment Approved by FDA

Since mesothelioma is often difficult to treat, scientists and researchers look to combination treatments and therapies to improve chances of patients’ survival. There is no “one” treatment that is used across the board in treating mesothelioma, because patients react differently, whether it is to chemotherapy, radiation therapy, immunotherapy, or surgery.  A research team from MD

more

Mesothelioma Treatments Used Alongside Surgery – A Clinical Trial

Rare and aggressive in nature, mesothelioma is often a fatal cancer mainly due to its lack of response to most treatments. Surgical options have a higher chance of success for those in the early stages of the disease, but since there is a long latency period between asbestos exposure and symptoms of mesothelioma, often times

more

Two Potential Mesothelioma Treatments Have No Positive Effect

Tremelimumab Earlier in the spring of 2017, scientists and researchers from the University of Salford in the UK published a special report questioning the effectiveness of the new immunotherapy treatment known as tremelimumab. Trials of the check point inhibitor did not show promising results and there was concern about the drug’s effectiveness, safety, and tolerability.

more

Improvements in Radiation Therapies Give More Treatment Options

When it comes to different treatments for mesothelioma patients, there is no shortage of diversity, as options include chemotherapy, radiation, surgery, immune-based therapies, gene-based therapies, and more. Chemotherapy treatments cisplatin and pemetrexed are first line treatments, especially among those who do not quality for surgery. Radiation treatment is available, but is typically the path less

more

Mesothelioma Patients Receive Zoledronic Acid as Treatment

Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health complications.  Nitrogen containing bisphosphonates like zoledronic acid are known to have cancer suppressing qualities, and scientists and researchers were eager to find out if zoledronic

more

Giving Cediranib Another Chance

A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is not the first time cediranib has been studied as a possible treatment for mesothelioma. In 2011/2012 a Phase II trial for cediranib conducted by researchers

more

Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early

Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help distinguish this cancer from other illnesses, but often patients will have already developed more serious symptoms because the cancer has spread by the time it

more

Pembrolizumab Update: Aduro Biotech Collaborates with Merck

A biopharmaceutical company named Aduro Biotech recently announced its collaboration with Merck to further evaluate the findings for the Phase II trial of KEYTRUDA ® (pembrolizumab) and to combine their own immunotherapy treatment, CRS-207. Information regarding KEYTRUDA ® treatment began to circulate late last year when data presented at the 17th World Conference on Lung

more

Last update: March 06, 2014. 08:41:31 pm.